Contact Congress about H.R. 1244: Reducing Drug Prices for Seniors Act

Medicare Part D plans would have to base your coinsurance on what they actually pay for a drug, not the higher list price. This could mean lower out-of-pocket costs for many seniors starting in 2026.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Reducing Drug Prices for Seniors Act is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 1244: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill primarily affects Medicare Part D enrollees who pay coinsurance on their prescriptions — especially those taking brand-name or specialty drugs where the gap between list price and actual price is largest. Insurance plans and drug manufacturers would also be affected, since rebates and discounts would directly influence what patients owe.

Why this matters: Many seniors currently pay coinsurance based on inflated list prices that don't reflect real market costs. This bill could meaningfully reduce what people pay at the pharmacy, especially for drugs with large rebates. However, the broader effects on premiums, plan design, and drug pricing are uncertain.

Key provisions in H.R. 1244

• Applies to Medicare Part D and MA-PD plans for formulary drugs that use coinsurance, not flat copays.
• Plans must base coinsurance on the drug's actual acquisition cost when it's lower than the wholesale list price.
• The new rule only covers costs between the annual deductible and the annual out-of-pocket cap under existing Medicare Part D law.
• The change takes effect for plan years starting on or after January 1, 2026.
• "Actual acquisition cost" means the negotiated price minus manufacturer rebates and discounts, based on data from the prior year's federal DIR Report.

How Modern Action helps you take action on H.R. 1244

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 1244

What is H.R. 1244?

Medicare Part D plans would have to base your coinsurance on what they actually pay for a drug, not the higher list price. This could mean lower out-of-pocket costs for many seniors starting in 2026.

How do I support or oppose H.R. 1244?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 1244?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain H.R. 1244 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.